Forty-seven male patients with mild essential hypertension were randomly allocated to three subgroups. After a run-in period of 4 weeks, the first subgroup (n=16) received propranolol (80 mg/day) for 36 weeks followed by a placebo period of 4 weeks. The second subgroup (n=15), after a run-in period of 4 weeks, was given a supplement of encapsulated fish oil (9 g/day) for 36 weeks with a subsequent period of 4 weeks in which fish oil placebo was given. The third subgroup (n=16), after a run-in period of 4 weeks, was given propranolol (80 mg/day) for 12 weeks, propranolol (80 mg/day) plus fish oil capsules (9 g/day equivalent to 1.8 g/day of eicosapentaenoic acid and 1.1 g/day of docosahexaenoic acid) for 12 weeks, propranolol plus fish oil placebo (same doses for 12 weeks) with a subsequent period of 4 weeks when propranolol placebo was administered. The results indicate a blood pressure-lowering effect of fish oil, which was comparable with that of propranolol. The simultaneous intake of fish oil plus propranolol was more effective than propranolol or fish oil alone. Propranolol treatment resulted in a decrease of plasma norepinephrine, plasma renin activity, and thromboxane B 2 formation. After fish oil supplementation, plasma norepinephrine and thromboxane B 2 formation were likewise reduced, whereas plasma renin activity appeared increased. The decrease of serum triglycerides, total and low density lipoprotein cholesterol as well as the rise of high density lipoprotein cholesterol are concomitant beneficial effects, which justify the consideration of fish oil alone or in combination with antihypertensive drugs for the treatment of mild hypertension. {Hypertension 1990;16:682-691)
P atients with mild hypertension are at higher risk for the development of cardiovascular disease. 1 " 3 Increasingly, in these subjects nonpharmacological treatment is recommended as an alternative regimen to early drug therapy, 4 -5 which is controversial or not yet indicated to reduce mildly elevated blood pressure. In young and middle-aged hypertensive patients, 0-adrenergic blockers are wellestablished therapy to lower high blood pressure. 6 On the other hand, several dietary means (e.g., salt and alcohol restriction, diet enriched with potassium and polyunsaturated fatty acids) have been proposed to treat mild hypertension. Recently, it was shown that n-3 polyunsaturated fatty acids supplemented with fish or fish oil had a blood pressure-lowering effect in normotensive volunteers 7 
"
10 and in patients with mild hypertension 11 " 15 irrespective of a beneficial influence on other risk factors. So far, clinical studies have been carried out to test the blood pressure-lowering effect using dietary n-3 polyunsaturated fatty acids as "monotherapy." Combinations of various dietary measures with or without drug treatment were scarcely reported in the literature. Therefore, the question arises of whether a comparison of fish oil supplementation with /3-blocker therapy provides information concerning the degree of their hypotensive efficacy in mild hypertension. Moreover, it might be of interest whether the concomitant supplementation of dietary n-3 polyunsaturated fatty acids during drug treatment can enhance the hypotensive action of the latter or might even be able to reduce its dosage.
The present study focuses on the former aspect using propranolol as one of the most common hypotensive drugs, fish oil supplementation, and the combination of both in fixed doses. In this preliminary trial only patients with mild essential hypertension were included.
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before the trial 166±8/99±5 mm Hg. The second group treated only with fish oil (group F) comprised 15 male patients: mean age 38.9±5.3 years, height 175±7 cm, weight 73.8±7.2 kg, blood pressure in recumbent position before the study 163±10/97±4 mm Hg. The third group (group P+F) treated with propranolol plus fish oil consisted of 16 male subjects: mean age 35.6±6.1 years, height 176±9 cm, weight 74.3 ±7.5 kg, blood pressure in recumbent position at selection of the patients (4 weeks before the trial) 164±9/98±4 mm Hg. Nobody was overweight according to the Quetelet index. Informed consent was obtained from all patients.
The patients of group P were seen twice before the study (before entry and at entry, that is, 4 weeks later) and then given propranolol (80 mg/day) for 36 weeks (3x12 weeks congruent with the treatment periods of group P+F) followed by a period of 4 weeks with propranolol placebo. During the treatment periods no other drugs, including analgesics, were taken. Two subjects who dropped out during the pretreatment period were excluded from the experiment.
The patients of group F were also seen twice before the trial and then given fish oil capsules (9 g/day equivalent to 1.8 g eicosapentaenoic acid [EPA] QO-J (n-3) and 1.1 g docosahexaenoic acid [DHA] C^ (H-3) for 36 weeks with a subsequent period of 4 weeks when fish oil placebo was provided. One subject who dropped out for personal reasons was excluded.
Group P+F underwent the following study design: Two visits including blood pressure measurement and blood sampling before the study (before entry and at entry, that is, 4 weeks later), propranolol monotherapy (80 mg/day) for 12 weeks, propranolol (80 mg/day)+fish oil capsules (9 g/day) for 12 weeks, propranolol (80 mg/day)+fish oil placebo (olive oil, 9 g/day) for 12 weeks, propranolol placebo for 4 weeks.
No control group without treatment was included in the experiment for ethical reasons because of the long duration of the study.
Propranolol (40 mg tablets) and propranolol placebo were given twice daily (in the morning and in the evening) and fish oil as well as fish oil placebo (both with peppermint taste) three times daily (at the main meals) in three gelatin capsules containing 1 g oil each. The fatty acid composition of fish oil and placebo (olive oil) can be seen in Table 1 . No adverse effects besides a fishy taste during the fish oil periods were reported by the participants at the visits. At the end of the pretreatment, treatment, and placebo periods the patients were seen for consultation, physical examination, blood pressure measurement, and blood sampling. Dietary protocols (diaries from 4 days) were obtained from each patient.
Blood pressure was measured in triplicate by the same observer using a random zero sphygmomanometer under strictly standardized conditions while the subject was in a recumbent position before venipuncture at 9:00 AM after 2 hours of rest (because of the 
Cn* (n-3) 'Eicosanoic and docosanoic acids were not subdivided according to the position of their double bond. subsequent blood withdrawal for the estimation of plasma renin activity [PRA]). The observer had no knowledge to which group or treatment period each patient belonged. Diastolic blood pressure was recorded at the disappearance of the Korotkoff sounds (phase 5). The values given are means of the second and third measurement. Thereafter, blood was taken from an antecubital vein for estimations of the parameters described below. All subjects fasted for at least 12 hours before blood sampling. They were asked to avoid alcohol in excess and to abstain from it completely for 1 day before blood sampling. Blood pressure after standing in an upright position for 1 minute was then measured in triplicate using the same sphygmomanometer. Again, values are given as means of the second and third measurement. Body weight (without jackets and shoes) was measured on standardized scales, revealing no major deviations during the study (not shown).
The dietary protocols likewise showed no significant differences in the intake of calories, fat, carbohydrates, and protein either between the groups of patients or between the treatment periods. In short, the mean intake of energy before the study (at entry) was 2,603 kcal/day, the percentages of carbohydrates: fat: protein were 51^32:17 in group P+F. The mean intake of sodium ranged from 55 to 6.6 g/day and the mean intake of potassium from 1.6 to 23 g/day within the single periods. The mean intake of energy in group P was 2,546 kcal/day, the percentages of carbohydrates : fat: protein were 49 ^ 33 : 18. The mean intake of sodium ranged from 5.3 to 6.7 g/day and that of potassium from 1.7 to 2.5 g/day. In group F, the mean The qualitative composition of food was equal in all isocaloric periods; only the fish oil or placebo oil (9 g/day) was supplemented in the two treatment periods to the diet in groups P+F and F. The mean fat intake was 91.4 g/day and the polyunsaturated/ saturated (p/s) ratio was 0.27 (mean of all three groups before the trial without significant differences between the groups). The latter increased insignificantly during the fish oil period to 0.34 in group P+F but fell slightly during the fish oil placebo period to 0.26. In group F, the p/s ratio rose to 0.32 and declined to 0.25 at the end of the placebo period. The changes, even if insignificant, might be due to the fact that the fish oil supplement (additional intake of 9 g fat/day) was balanced by a trifling reduction of saturated fat in the diet (i.e., a deletion of cold cuts: meat, sausage, or cheese) at dinner by choice of the participants. The subjects were asked to maintain their normal activities at work and at home. Besides control of the diets by instruction, interview, and protocol, the patient's compliance was tested by the fatty acid composition of serum phospholipids (compare Table 2 ).
Blood was centrifuged immediately (except a sample for thromboxane B2 [TXBJ formation, see below) and plasma or serum kept frozen at -20° C until analyses. After separation of the lipid classes by thin-layer chromatography and methylation, the fatty acid pattern of the phospholipids was estimated by gas-liquid chromatography as described earlier.
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Serum triglycerides and total cholesterol were determined using enzymatic methods (test sets from Boehringer/Mannheim, Mannheim, FRG). High density lipoprotein (HDL) cholesterol was estimated after precipitation with phosphorungstate and MgQ 2 . 18 Low density lipoprotein (LDL) cholesterol was calculated by Friedewald's formula, 19 as there were no samples with triglyceride levels above 3.5 mmol/1. Apolipoproteins A! and B were estimated by immunoelectrophoresis (Immuno AG, Wien, Austria). PRA was estimated by radioimmunoassay using a commercial test set (CEA-Ire-Sorin/RENK, St. Quentin Yvelines, France). Norepinephrine in heparinized plasma was determined by a radioenzymatic assay. 20 Because the concomitantly estimated plasma epinephrine and dopamine remained unchanged during the study, their values are not demonstrated. For the estimation of TXB2 formation, 10 ml blood was allowed to clot at 37° C for 1 hour 21 and serum was analyzed by radioimmunoassay. 22 The cross-reactivity with TXB3 was not tested.
Values are given as mean±SD. Statistical analyses before and after treatment were performed using Student's t test. Analyses of variance were performed for comparisons of both groups of patients. The levels of significance were accepted as/?<0.05 or/?<0.01. 2.3±0.9 EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; group P, patients receiving propranolol (80 mg/day) for 36 weeks; group F, patients receiving fish oil (9 g/day) for 36 weeks; group P+F, patients receiving propranolol (80 mg/day) for 12 weeks, propranolol (80 mg/day)+fish oil (9 g/day) for 12 weeks, and propranolol+fish oil placebo (olive oil, 9 g/day) for 12 weeks.
'Significance between successive treatment periods, p<0.01.
Results
In group F as well as in group P+F, at the end of the periods alone or additionally supplemented with fish oil for 12 weeks, EPA and DHA in serum phospholipids appeared significantly augmented as compared with the values before the diet, indicating the patients' compliance ( Table 2 ). In group P, no changes in the percentages of EPA and DHA were found.
In group P, systolic and diastolic blood pressures in the recumbent and upright positions were significantly reduced after 12 weeks of propranolol treatment and remained at this level throughout the propranolol period of 36 months. After the period with propranolol placebo, the blood pressure returned approximately to the initial levels (compare Figure 1) .
In group F, systolic and diastolic blood pressures in the recumbent and upright positions were significantly lower during the fish oil period. The decrease in systolic blood pressure was somewhat less pronounced when compared with the reduction by propranolol treatment in group P. After the period with BP, blood pressure; group P+F, patients receiving propranolol (80 mg/day) for 12 weeks, propranolol (80 mg/day)+fish oil (9 g/day) for 12 weeks, and propranolol (80 rag/day)+fish oil placebo (olive oil, 9 g/day) for 12 weeks; group P, patients receiving propranolol (80 mg/day) for 36 weeks; group F, patients receiving fish oil (9 g/day) for 36 weeks.
•Significance between successive treatment periods, p<0.0l. tSignificance between successive treatment periods, p<0.05. Significance versus pretreatment level, p< 0.01. §Significance versus pretreatment level (at entry),p<0.05.
fish oil placebo, the values returned nearly to the pretreatment levels (compare Figure 1) . In group P+F, systolic and diastolic blood pressures in the recumbent and upright positions were significantly lower in the first period on propranolol ( Table 3 ). The addition of fish oil led to a further significant decrease (compare Figure 1) . In the successive period with propranolol plus fish oil placebo, systolic and diastolic blood pressures increased to the level found in the period with propranolol alone.
In group P, the decrease of plasma norepinephrine was ascertained during the whole propranolol period (Table 4 ). It reached the initial level after the period in which propranolol placebo was given. In group F, plasma norepinephrine likewise appeared diminished during the whole period of supplementation with fish oil. This decrease was less pronounced when compared with propranolol treatment (group P). At the end of the period providing fish oil placebo the initial values were approximately reached. Plasma norepinephrine appeared lower after treatment with propranolol in group P+F and was further decreased at the end of the period additionally supplemented with fish oil (Table 4 ). In the following period with propranolol plus fish oil placebo, the plasma norepinephrine returned to the level with propranolol alone. After propranolol placebo, the values nearly reached the initial level.
In group P, there was likewise a depression of TXB 2 formation that continued throughout the whole treatment period (Table 4) . It increased in the period with propranolol placebo slightly exceeding the initial values. In group F, the significant decrease of TXB2 formation was of the same degree as compared with propranolol treatment in group P. After the period supplemented with fish oil placebo, the values increased nearly to the basal level. TXB2 formation was significantly depressed after the pro- pranolol period in group P+F (Table 4) . After the addition of fish oil, a further decrease was obvious. In the successive period with propranolol plus fish oil placebo, the level returned to the values found in the period with propranolol alone. In the last period on propranolol placebo, the values increased slightly exceeding the pretreatment level. In group P, PRA was significantly reduced during the whole treatment period and returned to a level slightly exceeding the pretreatment value after propranolol placebo (Table 4) . In group F, there was a significant rise of PRA during administration of fish oil and a subsequent fall to the initial level in the period supplemented with fish oil placebo. PRA was significantly decreased at the end of the propranolol period in group P+F (Table 4 ). In the subsequent period, the addition of fish oil resulted in a significant rise of PRA. During the period with propranolol plus fish oil, placebo PRA fell to the level found with propranolol alone. In the last period with propranolol placebo, again an increase of PRA was found; however, it did not reach the pretreatment level.
Serum triglycerides appeared significantly lower only at the end of the periods supplemented with fish oil (i.e., in groups F and P+F) ( Table 5 ). During the subsequent periods supplemented with fish oil placebo, the values increased slightly, exceeding the pretreatment level (compare Figure 2) . On the other hand, a slight elevation of triglycerides was found after 24 and 36 weeks of propranolol treatment (group P).
Total and LDL cholesterol likewise showed a significant fall at the end of the fish oil periods in groups F and P+F, returning to the initial levels at the end of the successive fish oil placebo periods (Table 5) . During propranolol treatment, no changes of total and LDL cholesterol were seen (compare Figure 3) .
HDL cholesterol revealed a significant increase after the fish oil periods in groups F and P+F (Table  5) . It reached the pretreatment values at the end of the subsequent periods when fish oil placebo was supplemented. No changes in HDL cholesterol were seen after propranolol monotherapy (group P).
Apolipoproteins A[ and B as well as fasting blood glucose remained unchanged in all periods of all groups (not demonstrated).
Discussion
The data described indicate the well-known hypotensive action of propranolol and that of fish oil supplementation. The latter was recently described in normotensive volunteers 7 2627 Thus, fish oil might be accepted as a novel factor in the array of dietary and pharmacological means to lower elevated blood pressure. Furthermore, our data show an additional effect of fish oil in mildly hypertensive patients already receiving propranolol monotherapy. In most of the studies, a dosage ranging from 1.5 to 6.0 g/day was used. In a recent carefully designed study based on continuous monitoring of blood pressure, 15 an antihypertensive effect in patients with mild hypertension was observed with a dose of fish oil as high as 50 ml/day. The efficacy of a lower dose of fish oil (9 g/day) in our trial might be due to the longer treatment periods (12 weeks and 36 weeks) as compared with the study (4 weeks) of Knapp and FitzGerald, 15 considering the accumulation of long TXB2, thromboxane B2; PRA, plasma renin activity; group P+F, patients receiving propranolol (80 mg/day) for 12 weeks, propranolol (80 mg/day)+fish oil (9 g/day) for 12 weeks, and propranolol+fish oil placebo (olive oil, 9 g/day) for 12 weeks; group P, patients receiving propranolol (80 mg/day) for 36 weeks; group F, patients receiving fish oil (9 g/day) for 36 weeks.
'Significance between successive treatment periods, p<0.01. tSignificance between successive treatment periods, p<0.05. *Significance versus pretreatment level, p<0.01. §Significance versus pretreatment level (at entry), p<0.05.
chain n-3 polyunsaturated fatty acids in membranes dependent not only on the daily dose but also on the duration of the n-3 polyunsaturated fatty acids intake.
Our study was conducted with fixed doses to evaluate the degree of the hypotensive action, when both /3-blocker and fish oil are compared and combined, respectively. Another possibility (e.g., the assessment of a drug-sparing effect of fish oil) was not considered in this trial. This should be pursued in further studies. Moreover, a control group without propranolol administration was not included for ethical reasons because of the long duration of the experiment. The choice of olive oil as placebo might be problematic because of its equivocal results on blood lipids and blood pressure. In some recent studies, safflower or corn oil was preferred. 14 - 15 However, no adverse or opposite effects were seen during the periods supplemented with fish oil placebo when compared with the run-in periods (-4 and 0 weeks, respectively).
Nevertheless, from the comparison of both groups (P and P+F), it can be concluded that the concomitant intake of £-blockers and fish oil might be an effective combination to reduce mildly elevated blood pressure. This could be of practical importance, as long-term control of hypertension should be based on the lowest effective doses, which most likely can be achieved with combination therapy. Furthermore, a lower rate of adverse effects can be expected with combination as compared with monocomponent treatment. The question to be answered next refers to whether the drug monotherapy can be discontinued when fish oil is added. This might be a pertinent consideration, as a significant hypotensive effect of fish diet or fish oil alone was reported by several groups 11 -14 in patients with mild essential hypertension.
In general, for clinical practice it seems to be reliable to start hypotensive therapy with a dietary regimen before drug treatment is considered. This suggests that an initial treatment with fish oil would have been effective in lowering blood pressure in a LDL, low density lipoproteins; HDL, high density lipoproteins; group P+F, patients receiving propranolol (80 mg/day) for 12 weeks, propranolol (80 mg/day)+fish oil (9 g/day) for 12 weeks, and propranolol+fish oil placebo (olive oil, 9 g/day) for 12 weeks; group P, patients receiving propranolol (80 mg/day) for 36 weeks; group F, patients receiving fish oil (9 g/day) for 36 weeks.
'Significance between successive treatment periods, p<0.01. tSignificance between successive treatment periods, p<0.05. Significance versus pretreatment level, p<0.01. §Significance versus pretreatment level (at entry), p<0.05.
portion of our patients. However, this was not the topic of the present experiment. The advantage of the preceding propranolol treatment might be that the effect of the additional fish oil supplementation was shown more clearly, indicating the amplified blood pressure-lowering action. Intensive dietary therapy after discontinuation of drug treatment resulted in a maintenance of lowered blood pressure in a considerable number of patients with mild essential hypertension. 28 The decrease of plasma norepinephrine by propranolol 29 ' 30 and fish oil is consistent with literature data from normotensive volunteers 10 but not from patients with mild essential hypertension. 11 Thus, a further decrease in plasma norepinephrine by the concomitant intake of propranolol and fish oil in group P+F might be unexpected. It could be speculated 11 that an augmented synthesis of prostaglandin I 3 , which was shown in humans after fish oil or fish diet, 31 might inhibit transmitter release 32 in accordance with the negative feedback postulated for transmitter release and prostaglandins of the 2-series. 33 A reduced PRA by propranolol has been described. 34 - 38 On the other hand, its elevation by fish oil agrees with a rise of PRA after short-term fish diet in patients with mild essential hypertension 11 and with high renin levels in Greenland Eskimos. 39 Prostaglandins of the 2-series stimulate renin secretion in the dog. 40 However, with dietary EPA no changes were found. 41 In humans, renin secretion by prostaglandins was likewise augmented. 42 " 44 This might be interpreted as a counterregulation that is insufficient to avoid the reduction of blood pressure.
The interpretation of the data on TXB2 formation is limited because of methodological problems, as the values obtained in plasma, platelets, or urine are not comparable. For instance, data on plasma TXBz normotensive subjects and patients with mild essential hypertension. The same objections must be considered when the decrease of urinary TXB2 metabolites by fish oil supplementation in normotensive subjects and of TXB2 formation in patients with mild essential hypertension in a previous study 12 and in the present study are interpreted. Urinary TXB2 metabolites were reduced by fish oil in the study of Knapp and FitzGerald. 15 The methodological objections reserved, it can be speculated that the decrease of TXB2 formation ex vivo after propranolol and fish oil and its further depression by the combination of both might be a contribution to their antihypertensive action. Propranolol treatment resulted in a slight increase of serum triglycerides but no significant changes in total, LDL, and HDL cholesterol were seen. The potential adverse effects of /3-blockers on serum lipids have been described. cholesterol by fish oil alone (group F) or by fish oil added to propranolol monotherapy (group P+F) might be of benefit from the preventive point of view. Interestingly, a rise of HDL cholesterol in addition to a fall of total and LDL cholesterol was found in patients with mild essential hypertension 11 - 12 but not in normotensive volunteers 10 in preceding studies using a mackerel diet. This beneficial effect supports the recommendation of n-3 polyunsaturated fatty acids as an additional means to lower blood pressure and serum lipids in mildly hypertensive patients, inasmuch as the hypotensive potency is of similar degree as compared with propranolol monotherapy. The great advantage of fish oil administration is its beneficial efficacy on several risk factors of coronary heart disease (e.g., hypertension, hyperlipoproteinemia, and increased platelet aggregability). 33 - 55 Because these risk factors, including hyperinsulinemia, 56 -57 are frequently found in patients with mild essential hypertension, it appears reliable to recommend therapeutic measures that might influence several of the disturbances involved. There is increasing evidence that other risk factors such as lipid disorders are at.least as potent as (mildly) elevated blood pressure to cause coronary heart disease. 58 -59 Provided this can be proven by long-term studies, fish oil supplementation could be assumed as a novel means of blood pressure control in mild hypertension. Its treatment includes not only the lowering of blood pressure but also the elimination of concomitant risk factors such as lipid disorders. 59 In addition, it is well-known that long chain n-3 polyunsaturated fatty acids provided with fish diet or fish oil have many other favorable effects such as reduced platelet aggregability, fibrinogen, blood viscosity, and inflammation as well as increased fibrinolysis and erythrocyte flexibility resulting in an improved microcirculation. Moreover, in mild hypertension the use of pressure-independent therapeutic measures might be of greater importance than in more severe forms of hypertension. 60 Therefore, a fish-rich diet or fish oil supplementation, in addition to other established dietary factors (e.g., weight reduction, salt restriction, potassium supplementation, alcohol restriction), might be a candidate for effective control not only of mildly elevated blood pressure but also of associated risk factors.
